From the Journals

Upadacitinib and Pain in RA, PsA

Mediation analysis suggests direct and indirect effects on pain reduction in rheumatoid and psoriatic arthritis.

Share

  • 1

    Upadacitinib effective in reducing pain in RA.

  • 2

    Greater efficacy than adalimumab and placebo.

  • 3

    SELECT-COMPARE and SELECT-PsA 1 trials used.

  • 4

    Significant pain improvement observed over 26 weeks.

  • 5

    Attenuation of inflammation leads to better treatment outcomes.

  • 6

    Residual pain can exist despite inflammation reduction.

Original Source(s)

Upadacitinib and Pain in RA, PsA

Mediation analysis suggests direct and indirect effects on pain reduction in rheumatoid and psoriatic arthritis.

  • by Kathryn Wighton

  • February 25, 2026

  • 4 min

Related Content

Selective JAK Inhibition in RA vs PV

Tofacitinib induced remission of rheumatoid arthritis but spared JAK2-driven polycythemia vera in a single case report.

Sleep Disorders Linked to Higher RA Prevalence

Results suggest sleep-related inflammation may play a role in RA, though causality remains unclear.

What's Really Driving Arthritis Pain?

A narrative review suggests pain in rheumatoid arthritis and osteoarthritis extends beyond nociceptive mechanisms.